We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Simple Saliva DNA Test Identifies Prostate Cancer Patients at Risk for Radiation Toxicity

By LabMedica International staff writers
Posted on 09 Jul 2024
Print article
Image: PROSTOX can predict an increased risk of late genitourinary toxicity from specific radiation therapies (Photo courtesy of MiraKind)
Image: PROSTOX can predict an increased risk of late genitourinary toxicity from specific radiation therapies (Photo courtesy of MiraKind)

Radiation therapy is the standard treatment for prostate cancer, but it can lead to long-lasting side effects like urinary and bowel complications, significantly affecting patients' quality of life. Globally, men with prostate cancer endure the highest number of years living with disabilities resulting from treatment side effects, underscoring both the high prevalence of the disease and the effectiveness of modern therapy in achieving high cure rates. Now, researchers are further advancing their work in personalizing cancer treatment to enhance the quality of life for prostate cancer patients by predicting and preventing severe long-term side effects caused by radiation therapy.

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center (Los Angeles, CA, USA) have received a USD 1.8 million grant from the National Cancer Institute (NCI, Bethesda, MD, USA) to validate and leverage biomarkers that predict adverse side effects from radiation therapy. Their study targets specific genetic markers known as mirSNPs, which are promising in predicting side effects from cancer treatments. A critical biomarker identified by the team, PROSTOX, has been shown to predict late genitourinary toxicity following advanced radiation therapy. PROSTOX is effective in predicting toxicity from two radiation therapy types: Stereotactic body radiation therapy (SBRT), which administers radiation in high doses over 5-7 sessions, and conventionally fractionated radiation therapy (CFRT), involving 35-45 sessions.

This test enables the assessment of whether a patient is at low or high risk for late genitourinary toxicity following SBRT or CFRT. Understanding the risk level can assist patients and physicians in selecting the most appropriate and safest treatment strategy. The researchers aim to further validate the predictive accuracy of PROSTOX in more patient groups. Additionally, they plan to explore the biological variations among patients with these biomarkers and assess the potential of highly targeted adaptive radiotherapy to minimize these and other side effects for all patients.

“By understanding the mirSNP genetic markers that predispose patients to adverse side effects from cancer therapy we can tailor these therapies to minimize harm and maximize efficacy,” said co-investigator Dr. Joanne Weidhaas, professor of radiation oncology, vice chair and head of translational research and co-developer of the PROSTOX test. “This work has the potential to improve the lives of countless patients.”

Related Links:
UCLA Health Jonsson Comprehensive Cancer Center
MiraDx
NCI

New
Gold Member
C-Reactive Protein Reagent
CRP Ultra Wide Range Reagent Kit
Unit-Dose Packaging solution
HLX
New
Automated Cell Counter
QuadCount
New
CVD Risk Test
GammaCoeur CVD Risk ELISA Test

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image: LMU’s Professor Frederick Klauschen developed the novel approach that can improve diagnostic accuracy (Photo courtesy of LMU Munich)

AI Tool Uses Imaging Data to Detect Less Frequent GI Diseases

Artificial intelligence (AI) is already being utilized in various medical fields, demonstrating significant potential in aiding doctors in diagnosing diseases through imaging data. However, training AI... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.